DermaSensor announces AI skincare device that detects three common skin cancers

The advanced development of medical technology has accelerated in recent years, with devices being continuously manufactured for healthcare professionals as well as consumers at home. From wellbeing wearables to AI smart mattresses, it's becoming more and more easier to access information about our health, giving us the opportunity to do something about it. Well, it's only getting better. 

It was announced yesterday that Medical technology manufacturer DermaSensor has been FDA cleared for its skin cancer detection device. The device works by shining light onto suspicious areas of the skin which are then analyzed by AI-powered algorithms, allowing potential skin cancers to be identified. 

One fifth of Americans will have had some type of skin cancer by the age of 70, and the annual cost of treating skin cancers in the US is estimated at $8.1 billion, with an estimated 5.5 million new cases each year. 

The good news is that 99% of skin cancers, including melanoma, are curable if detected early. Access to dermatology is challenging, especially in rural areas, which makes empowering primary care to identify those cases warranting a referral even more vital.

The release of the DermaSensor allows physicians who are not dermatologists to quickly diagnose common skin cancers with a high degree of confidence, therefore allowing patients to access necessary care in a timely manner. The company has conducted 13 clinical studies in the last decade, six of which provided the principal support for FDA clearance.

Whilst it's currently only available to registered physicians, who knows whether it could become widely accessible in the future? Interested physicians can join the DermaSensor waitlist today. 

Interested in more? Check out the 3 subtle health symptoms men should never ignore.